AI assistant
Sending…
Tempest Therapeutics, Inc. — Director's Dealing 2018
Dec 12, 2018
34632_dirs_2018-12-11_1655c35f-0b00-423c-9aa7-3c6bb2b47c6c.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 3 — Initial Statement of Beneficial Ownership
Issuer: Millendo Therapeutics, Inc. (MLND)
CIK: 0001544227
Period of Report: 2018-12-07
Reporting Person: WHITCOMB RANDALL W (Director)
More from Tempest Therapeutics, Inc.
Board/Management Information
2026
Jun 4
Regulatory Filings
2026
Jun 1
Board/Management Information
2026
May 29
Delisting Announcement
2026
May 22
Board/Management Information
2026
May 22
Interim / Quarterly Report
2026
May 14
Earnings Release
2026
May 14
Regulatory Filings
2026
May 6
Capital/Financing Update
2026
Apr 10
Capital/Financing Update
2026
Apr 10